Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Bladder Cancer
•
Medical Oncology
What is your preferred approach for neoadjuvant treatment for muscle invasive bladder cancer, have you switched to durvalumab plus gemcitabine cisplatin over dose dense or accelerated MVAC?
Related Questions
What are your top takeaways in GU Cancers from ESMO 2024?
What is your approach to muscle-invasive bladder cancer in a patient who is ineligible for surgery and radiotherapy?
Would you recommend "adjuvant" immunotherapy in a older, frail patient who received radiation for upper tract urothelial carcinoma?
Are patients with MIBC and bladder neck involvement good candidates for bladder preservation with chemoradiation after maximal, but not complete, TURBT?
Under what circumstances would it be appropriate to offer trimodality therapy (TMT) in muscle-invasive bladder cancer with localized variant histology?
How would you approach adjuvant therapy in MIBC with predominantly squamous cell differentiation?
Would you consider a treatment break for a patient with metastatic urothelial carcinoma who achieved a near-complete response to Enfortumab?
Is there a clinical benefit for a repeat TURBT to ensure complete resection of the bladder tumor prior to neoadjuvant chemotherapy and radical cystectomy?
What is your approach to a patient with muscle invasive bladder cancer getting neoadjuvant gemcitabine/cisplatin who develops significant ototoxicity due to cisplatin after two cycles?
Based on the results of the BladderPath trial, are you considering multiparametric bladder MRI for all patients with suspected bladder cancer diagnosis prior to TURBT, or for select patients only?
